公开(公告)号：US5656480A

公开(公告)日：1997-08-12

申请号：US374666

申请日：1995-01-27

Applicant: Carl T. Wild ,  Thomas J. Matthews ,  Dani P. Bolognesi

Inventor： Carl T. Wild ,  Thomas J. Matthews ,  Dani P. Bolognesi

IPC: C12N15/09 ,  A61K38/00 ,  A61P31/12 ,  C07K14/11 ,  C07K14/135 ,  C07K14/15 ,  C07K14/155 ,  C07K14/16 ,  C12N5/08 ,  A61K38/16

CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N2740/16122 ,  C12N2760/16022 ,  C12N2760/18522 ,  Y10S530/806

Abstract: This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.

Abstract translation: 本发明涉及具有抗病毒活性的人类免疫缺陷病毒（HIV）蛋白质片段，特别涉及抑制HIV诱导的细胞 - 细胞融合的HIV跨膜糖蛋白（gp41）的HIV肽。 本发明还涉及抑制包膜病毒感染的方法，以及调节涉及卷曲螺旋肽相互作用的生化过程的方法。

公开(公告)号：US4745055A

公开(公告)日：1988-05-17

申请号：US868393

申请日：1986-05-28

Applicant: Dale B. Schenk ,  Sharon K. Spratt

Inventor： Dale B. Schenk ,  Sharon K. Spratt

IPC: C07K14/11 ,  C07K14/58 ,  C07K14/785 ,  C12N9/38 ,  C12N15/62 ,  G01N33/535 ,  C12N15/00

CPC classification number: C07K14/005 ,  C07K14/58 ,  C07K14/785 ,  C12N15/62 ,  C12N9/2471 ,  C12Y302/01023 ,  G01N33/535 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2760/16022 ,  Y10S435/81

Abstract: A fused protein for use in an enzyme immunoassay system. The protein comprises an enzymatically active .beta.-galactosidase fused, at its C terminus, to an immunologically active peptide. The protein is produced using a plasmid containing a complete .beta.-galactosidase gene fused, at its 3' end, with an oligonucleotide coding for the peptide. The fused protein is designed for use in a solid-phase enzyme immunoassay system, based on immunospecific binding of the fused protein to a solid support, or in a homogeneous enzyme immunoassay system, based on enzyme inhibition resulting from immunospecific binding of an antibody to the protein.

Abstract translation: 用于酶免疫测定系统的融合蛋白。 蛋白质包含在其C末端融合到免疫活性肽的酶活性β-半乳糖苷酶。 使用含有完整的β-半乳糖苷酶基因的质粒在其3'末端与编码该肽的寡核苷酸融合来产生蛋白质。 融合蛋白被设计用于固相酶免疫测定系统，基于融合蛋白与固体支持物的免疫特异性结合，或在均相酶免疫测定系统中，基于由抗体与抗体的免疫特异性结合产生的酶抑制 蛋白。

公开(公告)号：US4631191A

公开(公告)日：1986-12-23

申请号：US747020

申请日：1985-06-20

Applicant: Beverly Dale ,  Barbara Cordell

Inventor： Beverly Dale ,  Barbara Cordell

IPC: C07K14/11 ,  A61K39/00 ,  A61K39/12 ,  C07K7/08 ,  C07K7/10

CPC classification number: C07K14/005 ,  C12N2760/16022 ,  Y10S530/806 ,  Y10S530/811

Abstract: Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagluttinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant synthesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes useful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.

Abstract translation: 公开了用于针对马流感病毒（EIV）免疫马的重组疫苗。 使用编码目前在马感染的两种EIV菌株的血凝素（HA）和神经氨酸酶（NA）糖蛋白的DNA序列来构建携带痘苗的疫苗，设计用于引物和加强给药的合成肽，并允许重组合成HA 和/或NA蛋白质疫苗。 这些DNA序列还提供了可用于从由遗传漂移产生的新菌株的新鲜分离物制备相似疫苗的探针。

公开(公告)号：US4474757A

公开(公告)日：1984-10-02

申请号：US335574

申请日：1981-12-29

Applicant: Ruth Arnon ,  Michal Shapira ,  Gunhild Muller

Inventor： Ruth Arnon ,  Michal Shapira ,  Gunhild Muller

IPC: A61K39/145 ,  C07K14/11 ,  A61K39/00 ,  A61K37/02 ,  C07C103/52 ,  C07G7/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K2039/55566 ,  A61K2039/6037 ,  A61K2039/6093 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16134 ,  Y10S514/888 ,  Y10S530/806 ,  Y10S530/807 ,  Y10S530/826 ,  Y10S930/29

Abstract: There is provided a synthetic vaccine against influenza virus infections consisting of a synthetic peptide corresponding to a relevant antigenic fragment of the virus, which fragment is attached to a suitable carrier, such as a macromolecule. Effective vaccinations against a plurality of strains can be obtained when the antigenic fragment is one common to such strains. Such synthetic vaccines are produced by synthesizing peptides corresponding to such relevant antigenic fragments and coupling same to a suitable carrier, such as a macromolecule. There is also provided a process for the vaccination of mammals against influenza which comprises applying to said mammals an effective quantity of a vaccine according to the invention.

Abstract translation: 提供了针对流感病毒感染的合成疫苗，其由对应于病毒的相关抗原性片段的合成肽组成，该片段连接到合适的载体，例如大分子。 当抗原片段是这些菌株共有的时，可以获得针对多种菌株的有效疫苗接种。 通过合成对应于这些相关抗原片段的肽并将其与合适的载体如大分子偶联来制备这样的合成疫苗。 还提供了一种针对流感的哺乳动物接种疫苗的方法，其包括向所述哺乳动物施用有效量的根据本发明的疫苗。

公开(公告)号：US11780888B2

公开(公告)日：2023-10-10

申请号：US17382625

申请日：2021-07-22

Applicant: Arlene I. Ramsingh ,  Janice Pata

Inventor： Arlene I. Ramsingh ,  Janice Pata

IPC: C07K14/005 ,  A61K39/215 ,  A61K49/00

CPC classification number: C07K14/005 ,  A61K39/215 ,  A61K49/00 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2770/20022 ,  C12N2770/20034

Abstract: The disclosure relates to a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 or a sequence having at least 97%-100% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 for use as an immunogen for the purpose of eliciting an immune response in a subject susceptible to infection with a coronavirus. The disclosed polypeptide is further useful in reducing the severity of symptoms associated with a coronavirus infection. In addition to use in a protein-based vaccine, the polypeptide of the disclosure can be encoded by a nucleic acid/ribonucleic acid and used in a nucleic acid vaccine or viral vector vaccine.

公开(公告)号：US20180326040A1

公开(公告)日：2018-11-15

申请号：US15776016

申请日：2016-11-16

Applicant: Kansas State University Research Foundation

Inventor： Ben Hause ,  Emily Collin

IPC: A61K39/145 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5256 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16322

Abstract: Attenuated live or replication-deficient chimeric swine influenza virus vaccine, and a platform to develop a multitude of other vaccines in swine and other species. The chimeric influenza virus A comprises a backbone of viral genomic segments derived from influenza A, and expresses a heterologous surface protein (influenza D hemagglutinin esterase fusion protein), and optionally at least one other heterologous protein, such as an antigenic component of a target pathogen.

公开(公告)号：US09550813B2

公开(公告)日：2017-01-24

申请号：US14401754

申请日：2013-05-22

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Yuan Lu ,  James R. Swartz

IPC: C07K14/005 ,  C12P21/02 ,  C12N7/00

CPC classification number: C07K14/005 ,  C07K2319/22 ,  C07K2319/35 ,  C07K2319/40 ,  C07K2319/42 ,  C07K2319/50 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2795/10122 ,  C12P21/02

Abstract: Intermolecular disulfide stabilized foldon polypeptides are provided.

Abstract translation: 提供了分子间二硫键稳定的折叠多肽。

公开(公告)号：US20160361438A1

公开(公告)日：2016-12-15

申请号：US15248902

申请日：2016-08-26

Applicant: CureVac AG

Inventor： Florian VON DER MÜLBE ,  Ingmar HOERR ,  Steve PASCOLO

IPC: A61K48/00 ,  A61K47/48 ,  A61K38/17 ,  C07K14/47

CPC classification number: A61K48/005 ,  A61K38/1735 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/193 ,  A61K38/28 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/0258 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K47/542 ,  A61K47/6455 ,  A61K48/00 ,  A61K48/0066 ,  A61K48/0075 ,  A61K48/0083 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/245 ,  C07K14/4727 ,  C07K14/4748 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N2310/334 ,  C12N2310/336 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2770/24122 ,  C12N2770/24134 ,  G16B20/00 ,  G16B30/00 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/416 ,  Y02A50/464 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.

公开(公告)号：US09290545B2

公开(公告)日：2016-03-22

申请号：US12864375

申请日：2010-07-23

Applicant: Loren D. Walensky ,  Gregory H. Bird

Inventor： Loren D. Walensky ,  Gregory H. Bird

IPC: C07K14/005 ,  A61K38/16

CPC classification number: C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

Abstract: The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

Abstract translation: 本发明提供了利用在稳定的α-螺旋结构（本文中也称为SAH）中具有病毒α-螺旋七肽重复结构域的多肽的组合物，试剂盒和方法。 该组合物可用于治疗和/或预防病毒感染。 本发明至少部分地基于本文提供的结果，证明病毒性碳氢化合物钉扎的α螺旋肽显示优异的蛋白水解，酸和热稳定性，恢复肽的天然α-螺旋结构，在干扰 病毒融合过程，并且与相应的未修饰的肽相比具有优异的药代动力学性质。

公开(公告)号：US20140302079A1

公开(公告)日：2014-10-09

申请号：US14346849

申请日：2012-09-24

Applicant: THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES

Inventor： Gary J. Nabel ,  Masaro Kanekiyo ,  Chih-Jen Wei ,  Patrick M. Mctamney ,  Hadi M. Yassine ,  Jeffrey C. Boyington

IPC: C07K14/205 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K39/105 ,  A61K39/12 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/205 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/35 ,  C07K2319/40 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/16134 ,  C12N2760/16234 ,  G01N33/56983

Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.

Abstract translation: 提供了引起广泛中和的抗流感抗体的新型疫苗。 一些疫苗包括在其表面上显示流感病毒的血凝素三聚体的纳米颗粒。 纳米颗粒包含融合蛋白，其包含与至少一部分流感血凝素蛋白结合的铁蛋白单体亚基。 一些部分包含胞外域，而一些部分限于茎区。 融合蛋白自组装形成血凝素显示纳米粒子。 一些疫苗仅包含连接到三聚结构域的流感血凝素蛋白的茎区。 这样的疫苗可用于接种个体，以抵抗来自获得纳米颗粒血凝素蛋白质的病毒的抗原性分歧的异源流感病毒和流感病毒感染。 还提供了编码这种蛋白质的融合蛋白和核酸分子。